KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Sales (2016 - 2025)

Historic Return on Sales for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to 0.31%.

  • Halozyme Therapeutics' Return on Sales fell 7700.0% to 0.31% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.23%, marking a year-over-year decrease of 2100.0%. This contributed to the annual value of 0.23% for FY2025, which is 2100.0% down from last year.
  • As of Q4 2025, Halozyme Therapeutics' Return on Sales stood at 0.31%, which was down 7700.0% from 0.49% recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Return on Sales ranged from a high of 1.87% in Q3 2021 and a low of 0.31% during Q4 2025
  • Moreover, its 5-year median value for Return on Sales was 0.4% (2024), whereas its average is 0.45%.
  • Its Return on Sales has fluctuated over the past 5 years, first soared by 13200bps in 2021, then crashed by -15700bps in 2022.
  • Halozyme Therapeutics' Return on Sales (Quarter) stood at 0.65% in 2021, then plummeted by -51bps to 0.32% in 2022, then increased by 17bps to 0.37% in 2023, then rose by 24bps to 0.46% in 2024, then tumbled by -168bps to 0.31% in 2025.
  • Its Return on Sales stands at 0.31% for Q4 2025, versus 0.49% for Q3 2025 and 0.51% for Q2 2025.